Champions Oncology, Inc. (CSBR) News

Champions Oncology, Inc. (CSBR): $7.25

-0.06 (-0.82%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CSBR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 494

in industry

Filter CSBR News Items

CSBR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CSBR News Highlights

  • CSBR's 30 day story count now stands at 4.
  • Over the past 16 days, the trend for CSBR's stories per day has been choppy and unclear. It has oscillated between 2 and 2.
  • The most mentioned tickers in articles about CSBR are DRUG.

Latest CSBR News From Around the Web

Below are the latest news stories about Champions Oncology Inc that investors may wish to consider to help them evaluate CSBR as an investment opportunity.

Champions Oncology-Fannin team up to develop therapeutics for tumors

Champions Oncology <> is collaborating with Fannin Innovation Studio to develop next generation therapeutics drug conjugates for tumors.The partnership will combine novel

Seeking Alpha | January 20, 2022

Champions Oncology Announces a Partnership with Fannin Innovation to Jointly Develop Therapeutic Raptamer Drug Conjugates

HACKENSACK, NJ / ACCESSWIRE / January 20, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, announced today a therapeutic co-development partnership with Fannin Innovation Studio.

Yahoo | January 20, 2022

Champions Oncology Announces a Partnership with Alloy Therapeutics to Develop Therapeutic Monoclonal Antibodies for Use in ADC Programs

HACKENSACK, NJ / ACCESSWIRE / January 4, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, announced today a therapeutic development partnership with Alloy Therapeutics.

Yahoo | January 4, 2022

Champions Oncology's (NASDAQ:CSBR) investors will be pleased with their impressive 149% return over the last five years

It hasn't been the best quarter for Champions Oncology, Inc. ( NASDAQ:CSBR ) shareholders, since the share price has...

Yahoo | January 4, 2022

Champions Oncology Inc (NASDAQ:CSBR) is debt free

Champions Oncology Inc (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, stock rose 3.23% (As The post Champions Oncology Inc (NASDAQ:CSBR) is debt free appeared first on FXDailyReport.Com .

FXDailyReport | December 14, 2021

Champions Oncology EPS beats by $0.02, beats on revenue

No summary available.

Seeking Alpha | December 13, 2021

Champions Oncology, Inc. (CSBR) Q2 2022 Earnings Call Transcript

Champions Oncology, Inc. (NASDAQ: CSBR) Q2 2022 earnings call dated Dec. 13, 2021. Corporate Participants: Ronnie Morris — President & Chief Executive Officer David Miller — Chief Financial Officer Analysts: Matt Hewitt — Craig-Hallum — Analyst […] The post Champions Oncology, Inc. (CSBR) Q2 2022 Earnings Call Transcript first appeared on AlphaStreet .

AlphaStreet | December 13, 2021

Champions Oncology Inc.''s (CSBR) CEO Ronnie Morris on Q2 2022 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | December 13, 2021

Champions Oncology, Inc.: Champions Oncology Reports Record Quarterly Revenue of $11.8 Million

Reported income from operations of $263,000HACKENSACK, NJ / ACCESSWIRE / December 13, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming…

FinanzNachrichten | December 13, 2021

Champions Oncology Reports Record Quarterly Revenue of $11.8 Million

Reported income from operations of $263,000HACKENSACK, NJ / ACCESSWIRE / December 13, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, today announced its financial results for its second quarter of fiscal 2022, ended October 31, 2021.

Yahoo | December 13, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6093 seconds.